phosphorylcholine has been researched along with Disease Models, Animal in 145 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the biological and molecular functions of LRs in colorectal cancer (CRC) by using an LR-disrupting alkylphospholipid (APL) drug, miltefosine." | 8.02 | Lipid raft-disrupting miltefosine preferentially induces the death of colorectal cancer stem-like cells. ( Baek, JH; Choi, JH; Kim, JH; Lee, CJ; Lee, WJ; Nam, JS; Park, S; Park, SY; Park, ZY, 2021) |
| "A dual drug repurposing/nanotechnological approach was used to develop an alternative oral treatment for schistosomiasis mansoni using miltefosine (MFS), an anticancer alkylphosphocholine, and lipid nanocapsules (LNCs) as oral nanovectors." | 7.83 | Miltefosine lipid nanocapsules: Intersection of drug repurposing and nanotechnology for single dose oral treatment of pre-patent schistosomiasis mansoni. ( Eissa, MM; El-Azzouni, MZ; El-Khordagui, LK; El-Moslemany, RM; Ramadan, AA, 2016) |
| "This study demonstrates that prenatal choline deficiency has profound effects by delaying neurodevelopment as evidenced by structural and metabolic MRI assessments." | 7.83 | Perinatal choline deficiency delays brain development and alters metabolite concentrations in the young pig. ( Dilger, RN; Getty, CM; Mudd, AT; Sutton, BP, 2016) |
| " We assessed the therapeutic potential of tuftsin-PC conjugate (TPC) to attenuate murine colitis." | 7.81 | Phosphorylcholine-tuftsin compound prevents development of dextransulfate-sodium-salt induced murine colitis: implications for the treatment of human inflammatory bowel disease. ( Barshak, I; Bashi, T; Ben-Ami Shor, D; Bizzaro, G; Blank, M; Fridkin, M; Lachnish, J; Shoenfeld, Y, 2015) |
| "This in vivo study demonstrates that a miltefosine-polyhexamethylene biguanide combination is highly effective for the treatment of Acanthamoeba keratitis." | 7.80 | Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis. ( Arici, MK; Dursun, A; Obwaller, A; Polat, ZA; Vural, A; Walochnik, J, 2014) |
| "Miltefosine inhibits T-cell proliferation and effectively reduces inflammation in the T-cell transfer model." | 7.79 | Miltefosine suppresses inflammation in a mouse model of inflammatory bowel disease. ( Duijvestein, M; Hommes, DW; Meijer, SL; Peppelenbosch, MP; te Velde, AA; van den Brink, GR; Verhaar, AP; Vos, AC; Wildenberg, ME, 2013) |
| " The purpose of this study was to determine the efficacy of local methylprednisolone (MP) delivery using PC-coated stents to inhibit inflammatory response and in-stent neointimal hyperplasia in an overstretched porcine coronary model." | 7.72 | Local methylprednisolone delivery using a BiodivYsio phosphorylcholine-coated drug-delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model. ( De Scheerder, I; Huang, Y; Li, S; Liu, X; Verbeken, E; Wang, L, 2003) |
| "Lenses exposed to high concentrations of xylose in organ culture produce xylitol, and they lose transparency and exhibit other changes characteristic of cataracts." | 7.70 | Effects of xylose on monkey lenses in organ culture: a model for study of sugar cataracts in a primate. ( Blum, PS; Jernigan, HM; Liu, Y; Merola, LO; Stimbert, CD; Zigler, JS, 1998) |
| "Miltefosine was originally formulated and registered as a topical treatment for cutaneous cancers." | 6.43 | Development of miltefosine as an oral treatment for leishmaniasis. ( Engel, J; Sindermann, H, 2006) |
| "Phosphorylcholine (PC) is an important pro-inflammatory damage-associated molecular pattern." | 5.62 | Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases. ( Bergman, A; Dahlbom, I; de Jong, RCM; de Vries, MR; Ewing, MM; Frostegård, J; Jukema, JW; Karabina, SAP; Karper, JC; Kuiper, J; MacArthur, MR; Mitchell, JR; Ninio, E; Nordzell, M; Peters, EAB; Pettersson, K; Quax, PHA; Sexton, D, 2021) |
| "The treatment with miltefosine demonstrated significantly lower subcutaneous lesion areas compared to the control group but was not sufficient for the complete remission of the lesions." | 5.56 | Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits. ( Alves, SH; de Andrade, CM; de Jesus, FPK; Engelmann, AM; Kommers, GD; Loreto, ES; Santurio, JM; Silva, TM; Tondolo, JSM; Zanette, RA, 2020) |
| "Glomerulonephritis was addressed by detection of proteinuria, and immunoglobulin complex deposition in the mesangium of the kidneys of the mice by immunofluorescence." | 5.42 | Successful modulation of murine lupus nephritis with tuftsin-phosphorylcholine. ( Barshak, I; Bashi, T; Ben-Ami Shor, D; Blank, M; Fridkin, M; Gendelman, O; Shoenfeld, Y; Versini, M; Volkov, A, 2015) |
| "Acanthamoeba keratitis is a painful corneal infection and difficult to treat because no sufficiently efficient drug has yet been available." | 5.38 | Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters. ( Obwaller, A; Polat, ZA; Vural, A; Walochnik, J, 2012) |
| "Perifosine-treated mice bearing xenograft NB tumors had longer survival than untreated mice (untreated vs treated, median survival: AS, 13 days, 95% confidence interval [CI] = 11 to 16 days vs not reached, P = ." | 5.36 | In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine. ( Li, Z; Liewehr, DJ; Steinberg, SM; Tan, F; Thiele, CJ, 2010) |
| "Miltefosine was fungicidal for C." | 5.33 | Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. ( Ellis, DH; Ganendren, R; Handke, R; Obando, D; Sorrell, TC; Widmer, F; Wright, LC, 2006) |
| "This study evaluated the biological and molecular functions of LRs in colorectal cancer (CRC) by using an LR-disrupting alkylphospholipid (APL) drug, miltefosine." | 4.02 | Lipid raft-disrupting miltefosine preferentially induces the death of colorectal cancer stem-like cells. ( Baek, JH; Choi, JH; Kim, JH; Lee, CJ; Lee, WJ; Nam, JS; Park, S; Park, SY; Park, ZY, 2021) |
| "This study demonstrates that prenatal choline deficiency has profound effects by delaying neurodevelopment as evidenced by structural and metabolic MRI assessments." | 3.83 | Perinatal choline deficiency delays brain development and alters metabolite concentrations in the young pig. ( Dilger, RN; Getty, CM; Mudd, AT; Sutton, BP, 2016) |
| "A dual drug repurposing/nanotechnological approach was used to develop an alternative oral treatment for schistosomiasis mansoni using miltefosine (MFS), an anticancer alkylphosphocholine, and lipid nanocapsules (LNCs) as oral nanovectors." | 3.83 | Miltefosine lipid nanocapsules: Intersection of drug repurposing and nanotechnology for single dose oral treatment of pre-patent schistosomiasis mansoni. ( Eissa, MM; El-Azzouni, MZ; El-Khordagui, LK; El-Moslemany, RM; Ramadan, AA, 2016) |
| " We assessed the therapeutic potential of tuftsin-PC conjugate (TPC) to attenuate murine colitis." | 3.81 | Phosphorylcholine-tuftsin compound prevents development of dextransulfate-sodium-salt induced murine colitis: implications for the treatment of human inflammatory bowel disease. ( Barshak, I; Bashi, T; Ben-Ami Shor, D; Bizzaro, G; Blank, M; Fridkin, M; Lachnish, J; Shoenfeld, Y, 2015) |
| "This in vivo study demonstrates that a miltefosine-polyhexamethylene biguanide combination is highly effective for the treatment of Acanthamoeba keratitis." | 3.80 | Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis. ( Arici, MK; Dursun, A; Obwaller, A; Polat, ZA; Vural, A; Walochnik, J, 2014) |
| "Miltefosine inhibits T-cell proliferation and effectively reduces inflammation in the T-cell transfer model." | 3.79 | Miltefosine suppresses inflammation in a mouse model of inflammatory bowel disease. ( Duijvestein, M; Hommes, DW; Meijer, SL; Peppelenbosch, MP; te Velde, AA; van den Brink, GR; Verhaar, AP; Vos, AC; Wildenberg, ME, 2013) |
| "To assess the effect of irinotecan-eluting stents (IS) on neointimal growth in the aortas of hypercholesterolemic rabbits and to determine other local histopathological effects such as necrosis, fibrin, and inflammatory reaction." | 3.73 | Irinotecan-eluting stents inhibited neointimal proliferation in hypercholesterolemic rabbit aortas. ( Berrocal, DH; Gelpi, RJ; González, GE; Grinfeld, LR; Morales, C, 2006) |
| "Selenite cataract was induced by injecting 13-day-old Sprague-Dawley rat pups with a single subcutaneous dose of sodium selenite (3." | 3.73 | Biochemical changes in selenite cataract model measured by high-resolution MAS H NMR spectroscopy. ( Fris, M; Midelfart, A; Saether, O; Tessem, MB, 2006) |
| " The purpose of this study was to determine the efficacy of local methylprednisolone (MP) delivery using PC-coated stents to inhibit inflammatory response and in-stent neointimal hyperplasia in an overstretched porcine coronary model." | 3.72 | Local methylprednisolone delivery using a BiodivYsio phosphorylcholine-coated drug-delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model. ( De Scheerder, I; Huang, Y; Li, S; Liu, X; Verbeken, E; Wang, L, 2003) |
| "Lenses exposed to high concentrations of xylose in organ culture produce xylitol, and they lose transparency and exhibit other changes characteristic of cataracts." | 3.70 | Effects of xylose on monkey lenses in organ culture: a model for study of sugar cataracts in a primate. ( Blum, PS; Jernigan, HM; Liu, Y; Merola, LO; Stimbert, CD; Zigler, JS, 1998) |
| "Patients with liver cirrhosis of different aetiologies are at a risk to develop HCC." | 2.66 | Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma. ( Aslanidis, C; Buechler, C, 2020) |
| "High-grade gliomas (WHO grade III anaplastic astrocytoma and grade IV glioblastoma multiforme) are the most common primary tumors in the central nervous system in adults." | 2.45 | High-grade glioma mouse models and their applicability for preclinical testing. ( Beijnen, JH; de Vries, NA; van Tellingen, O, 2009) |
| "Miltefosine was originally formulated and registered as a topical treatment for cutaneous cancers." | 2.43 | Development of miltefosine as an oral treatment for leishmaniasis. ( Engel, J; Sindermann, H, 2006) |
| "Phosphorylcholine (PC) is an important pro-inflammatory damage-associated molecular pattern." | 1.62 | Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases. ( Bergman, A; Dahlbom, I; de Jong, RCM; de Vries, MR; Ewing, MM; Frostegård, J; Jukema, JW; Karabina, SAP; Karper, JC; Kuiper, J; MacArthur, MR; Mitchell, JR; Ninio, E; Nordzell, M; Peters, EAB; Pettersson, K; Quax, PHA; Sexton, D, 2021) |
| "Phosphorylcholine is a pro-inflammatory epitope exposed on apoptotic cells, and phosphorylcholine monoclonal immunoglobulin (Ig)G antibodies (PC-mAb) have anti-inflammatory properties." | 1.62 | Phosphorylcholine antibodies restrict infarct size and left ventricular remodelling by attenuating the unreperfused post-ischaemic inflammatory response. ( Atsma, DE; de Jong, RCM; de Vries, MR; Jukema, JW; Pettersson, K; Pluijmert, NJ; Quax, PHA, 2021) |
| "The treatment with miltefosine demonstrated significantly lower subcutaneous lesion areas compared to the control group but was not sufficient for the complete remission of the lesions." | 1.56 | Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits. ( Alves, SH; de Andrade, CM; de Jesus, FPK; Engelmann, AM; Kommers, GD; Loreto, ES; Santurio, JM; Silva, TM; Tondolo, JSM; Zanette, RA, 2020) |
| "Unlike an untreated PEEK valve, no thrombus formed on the PEEK-g-PMPC valves on gross anatomy examination in addition to the absence of traveled thrombi in the kidney and lung tissues." | 1.51 | Short-term evaluation of thromboresistance of a poly(ether ether ketone) (PEEK) mechanical heart valve with poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC)-grafted surface in a porcine aortic valve replacement model. ( Fukazawa, K; Ishihara, K; Kakinoki, S; Kambe, Y; Kyomoto, M; Liu, Y; Mahara, A; Minatoya, K; Tanaka, H; Yamaoka, T, 2019) |
| "Visceral leishmaniasis is a neglected parasitic disease with no vaccine available and its pharmacological treatment is reduced to a limited number of unsafe drugs." | 1.51 | A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery. ( Álvarez-Velilla, R; Balaña-Fouce, R; Fresno, M; Gutiérrez-Corbo, MDC; Pérez-Pertejo, MY; Punzón, C; Reguera, RM, 2019) |
| "Topical treatment for cutaneous leishmaniasis (CL) would be useful for treatment of some forms of the disease." | 1.51 | Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis. ( Escobar, P; Mantilla, JC; Neira, LF, 2019) |
| "Perifosine pretreatment suppressed the KA-induced neuronal death and mossy fiber sprouting." | 1.48 | Akt Inhibitor Perifosine Prevents Epileptogenesis in a Rat Model of Temporal Lobe Epilepsy. ( Chen, L; Dong, J; Kai, J; Wang, Q; Wu, M; Zeng, LH; Zhu, F, 2018) |
| " In vivo, we further revealed that the chronic administration of low-doses of paclitaxel - i." | 1.46 | Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression. ( André, N; Berges, R; Borge, L; Bourgarel, V; Braguer, D; Buric, D; Carré, M; Carrier, A; Le Grand, M; Montero, MP; Pasquier, E; Vasseur, S, 2017) |
| "Severe influenza diseases with high mortality have been frequently reported, especially in those patients infected with avian influenza A (H5N1, H7N9 or H10N8) or during a pandemic." | 1.46 | C-Reactive Protein Mediating Immunopathological Lesions: A Potential Treatment Option for Severe Influenza A Diseases. ( Bai, T; Bo, H; Gao, R; Shu, Y; Wang, L; Zhang, Y, 2017) |
| " Pharmacokinetic parameters were estimated using non-compartmental analysis." | 1.46 | Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. ( Cruz, R; Figg, WD; League-Pascual, JC; Lester-McCully, CM; Peer, CJ; Rodgers, L; Ronner, L; Shandilya, S; Warren, KE, 2017) |
| "Single oral doses of 20, 50 and 100 mg/kg were administered for pharmacokinetic analysis while a 100 mg/kg single oral dose was given on day 7, 4 or 1, or 4 h prior to infection in the prophylactic efficacy study." | 1.43 | Pharmacokinetics and pharmacodynamics of oleylphosphocholine in a hamster model of visceral leishmaniasis. ( Dorlo, TP; Fortin, A; Hendrickx, S; Maes, L, 2016) |
| "Robust deposition of IgM within atherosclerotic plaques could also be readily observed in both control and experimental mice." | 1.43 | Atherosclerosis Susceptibility in Mice Is Independent of the V1 Immunoglobulin Heavy Chain Gene. ( Binder, CJ; Centa, M; Gruber, S; Hansson, GK; Johansson, DK; Ketelhuth, DF; Malin, S; Nilsson, D; Polyzos, KA, 2016) |
| "Tamoxifen was able to hinder the emergence of miltefosine resistance." | 1.43 | Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis. ( Coelho, AC; Reimão, JQ; Trinconi, CT; Uliana, SR, 2016) |
| "Choline is an essential nutrient, and its deficiency is related to PN-associated organ diseases." | 1.43 | Choline Alleviates Parenteral Nutrition-Associated Duodenal Motility Disorder in Infant Rats. ( Cai, W; Guo, Y; Huang, H; Lu, T; Tang, Q; Wu, Y; Zhu, J, 2016) |
| "Glomerulonephritis was addressed by detection of proteinuria, and immunoglobulin complex deposition in the mesangium of the kidneys of the mice by immunofluorescence." | 1.42 | Successful modulation of murine lupus nephritis with tuftsin-phosphorylcholine. ( Barshak, I; Bashi, T; Ben-Ami Shor, D; Blank, M; Fridkin, M; Gendelman, O; Shoenfeld, Y; Versini, M; Volkov, A, 2015) |
| " fumigatus mouse model, adopting a short-term and long-term oral or intraperitoneal dosing regimen." | 1.42 | Efficacy of oleylphosphocholine (OlPC) in vitro and in a mouse model of invasive aspergillosis. ( Bosschaerts, T; Boulet, G; Cos, P; Fortin, A; Maes, L; Paulussen, C, 2015) |
| "Miltefosine was the first oral compound approved for visceral leishmaniasis chemotherapy, and its efficacy against Leishmania donovani has been well documented." | 1.40 | In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis. ( Coelho, AC; Costa, CH; Trinconi, CT; Uliana, SR, 2014) |
| " Initial dose-response experiments showed that an oral daily dose of 40 mg/kg of OlPC was needed to impact time to cure and lesion sizes." | 1.40 | Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis. ( Bosschaerts, T; Caridha, DP; Fortin, A; Grogl, M; Hickman, MR; Hudson, TH; Leed, S; Ngundam, F; Parriott, S; Sena, J, 2014) |
| "Miltefosine was investigated for its activity against Neospora caninum tachyzoites in vitro, and was shown to inhibit the proliferation of N." | 1.38 | Effects of miltefosine treatment in fibroblast cell cultures and in mice experimentally infected with Neospora caninum tachyzoites. ( Debache, K; Hemphill, A, 2012) |
| "Acanthamoeba keratitis is a painful corneal infection and difficult to treat because no sufficiently efficient drug has yet been available." | 1.38 | Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters. ( Obwaller, A; Polat, ZA; Vural, A; Walochnik, J, 2012) |
| "Combination therapy for the treatment of visceral leishmaniasis has increasingly been advocated as a way to increase treatment efficacy and tolerance, to reduce treatment duration and cost, and to limit the emergence of drug resistance." | 1.37 | Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis. ( Gupta, S; Sane, SA; Shakya, N, 2011) |
| "Miltefosine has structural similarity to the PC and sphingomyelin substrates of PlcHR, and we found that it inhibits the cleavage of these choline-containing lipids in vitro." | 1.37 | Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection. ( Allard, JL; Allen, GB; Gross, MJ; Hogan, DA; Leclair, LW; Lundblad, LK; Rajamani, S; Vasil, ML; Wargo, MJ, 2011) |
| "Perifosine-treated mice bearing xenograft NB tumors had longer survival than untreated mice (untreated vs treated, median survival: AS, 13 days, 95% confidence interval [CI] = 11 to 16 days vs not reached, P = ." | 1.36 | In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine. ( Li, Z; Liewehr, DJ; Steinberg, SM; Tan, F; Thiele, CJ, 2010) |
| "Miltefosine was administered orally at 25 mg/kg/day for 10 days, while 10% paromomycin gel was applied topically twice a day for 10 days." | 1.35 | Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens. ( Aguiar, MG; Fernandes, AP; Ferreira, LA; Nunan, EA; Nunan, FA; Silva, DL, 2009) |
| "Pre-treatment with mecamylamine (50 mug; i." | 1.35 | Peripheral administration of CDP-choline, phosphocholine or choline increases plasma adrenaline and noradrenaline concentrations. ( Cansev, M; Hamurtekin, E; Ilcol, YO; Ulus, IH; Yilmaz, MS, 2008) |
| "Treatment with LAQ824 resulted in altered phospholipid metabolism and compromised tumor bioenergetics." | 1.35 | Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. ( Aherne, W; Atadja, P; Beloueche-Babari, M; Chung, YL; Griffiths, JR; Jackson, LE; Judson, IR; Kristeleit, R; Leach, MO; Troy, H; Workman, P, 2008) |
| "Although prostate cancer in TRAMP mice shares some metabolic features with that in humans, it differs with respect to choline phospholipid metabolism, which could impact upon the interpretation of results from biomarker or chemotherapy/chemoprevention studies." | 1.35 | Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism. ( Edwards, RE; Farmer, PB; Gant, TW; Gescher, AJ; Greaves, P; Jones, DJ; Keun, HC; Steward, WP; Teahan, O; Teichert, F; Verschoyle, RD; Wilson, ID, 2008) |
| "Retinal detachments were created in adult pigmented rabbits." | 1.34 | The effect of alkylphosphocholines on intraretinal proliferation initiated by experimental retinal detachment. ( Betts, K; Eibl, KH; Fisher, SK; Gandorfer, A; Kampik, A; Lewis, GP; Linberg, KA, 2007) |
| "In animal models of IgA nephropathy, the inevitable endogenous immune response to passively administered antigens alone or in complex with specific IgA mask the exact role each might play in pathogenesis." | 1.33 | The endogenous immune response modulates the course of IgA-immune complex mediated nephropathy. ( Chao, TK; Chen, A; Ka, SM; Kung, JT; Lee, WH; Lin, YF; Rifai, A; Shui, HA; Sytwu, HK; Yang, SM, 2006) |
| "Miltefosine was fungicidal for C." | 1.33 | Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. ( Ellis, DH; Ganendren, R; Handke, R; Obando, D; Sorrell, TC; Widmer, F; Wright, LC, 2006) |
| " Further study is necessary to determine the dose-response and long-term effects ABT-578-eluting stents in the porcine coronary model." | 1.33 | Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model. ( Carter, AJ; Collingwood, R; Gibson, L; Sedlik, S; Virmani, R, 2005) |
| "SCA3 or Machado-Joseph disease (MJD) is the commonest dominant inherited ataxia disease, with pathological phenotypes apparent with a CAG triplet repeat length of 61-84." | 1.32 | Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3. ( Cemal, CK; Griffin, JL; Pook, MA, 2004) |
| "Brain cells in Alzheimer's disease (AD) exhibit a membrane defect characterized by accelerated phospholipid turnover." | 1.31 | Acceleration of phosphatidylcholine synthesis and breakdown by inhibitors of mitochondrial function in neuronal cells: a model of the membrane defect of Alzheimer's disease. ( Blusztajn, JK; Farber, SA; Slack, BE, 2000) |
| "Infantile hydrocephalus is most often caused by an obstruction in the cerebrospinal fluid flow pathway and results in ventricular dilatation and chronic trauma to the surrounding brain." | 1.30 | Progressive changes in cortical metabolites at three stages of infantile hydrocephalus studied by in vitro NMR spectroscopy. ( Andersohn, RW; Harris, NG; Jones, HC; Rocca, JR, 1997) |
| " Conventional non-compartmental pharmacokinetic analysis and an elaborate three- and four-compartmental model were used for explaining the experimental data." | 1.30 | Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice. ( Arndt, D; Fahr, A; Fichtner, I; Teppke, AD; Zeisig, R, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.69) | 18.7374 |
| 1990's | 11 (7.59) | 18.2507 |
| 2000's | 37 (25.52) | 29.6817 |
| 2010's | 79 (54.48) | 24.3611 |
| 2020's | 17 (11.72) | 2.80 |
| Authors | Studies |
|---|---|
| Park, SY | 1 |
| Kim, JH | 1 |
| Choi, JH | 1 |
| Lee, CJ | 1 |
| Lee, WJ | 1 |
| Park, S | 2 |
| Park, ZY | 1 |
| Baek, JH | 1 |
| Nam, JS | 1 |
| Ramot, Y | 1 |
| Dolkart, O | 1 |
| Steiner, M | 1 |
| Jahn, S | 1 |
| Goldberg, R | 1 |
| Cacical, O | 1 |
| Lavie, Y | 1 |
| Ezov, N | 1 |
| Agar, G | 1 |
| Nyska, A | 1 |
| Kim, DS | 1 |
| Na, HS | 1 |
| Cho, KH | 1 |
| Lee, KH | 1 |
| Choi, J | 1 |
| Kwok, SK | 1 |
| Bae, YS | 1 |
| Cho, ML | 1 |
| Park, SH | 1 |
| Carregal, VM | 1 |
| Lanza, JS | 1 |
| Souza, DM | 1 |
| Islam, A | 1 |
| Demicheli, C | 1 |
| Fujiwara, RT | 1 |
| Rivas, L | 1 |
| Frézard, F | 1 |
| Dar, MJ | 1 |
| Khalid, S | 1 |
| McElroy, CA | 1 |
| Satoskar, AR | 1 |
| Khan, GM | 1 |
| Loreto, ES | 1 |
| Tondolo, JSM | 1 |
| de Jesus, FPK | 1 |
| Engelmann, AM | 1 |
| de Andrade, CM | 1 |
| Santurio, JM | 1 |
| Zanette, RA | 1 |
| Kommers, GD | 1 |
| Silva, TM | 1 |
| Alves, SH | 1 |
| Kang, S | 1 |
| Kim, J | 1 |
| Kim, S | 1 |
| Wufuer, M | 1 |
| Kim, Y | 2 |
| Choi, D | 1 |
| Jin, X | 2 |
| Huang, Y | 2 |
| Jeon, B | 1 |
| Choi, TH | 1 |
| Park, JU | 1 |
| Lee, Y | 2 |
| Wu, Z | 1 |
| Chen, B | 1 |
| Gan, Z | 1 |
| Chen, F | 1 |
| Luo, X | 1 |
| Buechler, C | 1 |
| Aslanidis, C | 1 |
| Barakat, AM | 2 |
| Saafan, AE | 1 |
| Melek, ST | 1 |
| Behour, TS | 1 |
| Khairy, NM | 1 |
| Khairalla, AS | 1 |
| Ferreira, C | 2 |
| Mesquita, I | 1 |
| Barbosa, AM | 1 |
| Osório, NS | 1 |
| Torrado, E | 1 |
| Beauparlant, CJ | 1 |
| Droit, A | 1 |
| Cunha, C | 1 |
| Carvalho, A | 1 |
| Saha, B | 1 |
| Estaquier, J | 1 |
| Silvestre, R | 1 |
| Cheng, Z | 1 |
| Abrams, ST | 1 |
| Toh, J | 1 |
| Wang, SS | 1 |
| Downey, C | 1 |
| Ge, X | 1 |
| Yu, Q | 1 |
| Yu, W | 1 |
| Wang, G | 1 |
| Toh, CH | 1 |
| Eberhardt, E | 4 |
| Hendrickx, R | 1 |
| Van den Kerkhof, M | 2 |
| Monnerat, S | 1 |
| Alves, F | 1 |
| Hendrickx, S | 5 |
| Maes, L | 6 |
| Caljon, G | 2 |
| Li, WJ | 1 |
| Liao, HH | 1 |
| Feng, H | 1 |
| Zhou, ZY | 1 |
| Mou, SQ | 1 |
| Zhang, N | 1 |
| Wu, HM | 1 |
| Xia, H | 1 |
| Tang, QZ | 1 |
| Kadowaki, Y | 1 |
| Hirano, T | 1 |
| Fujita, K | 1 |
| Kawano, T | 1 |
| Matsunaga, T | 1 |
| Yoshinaga, K | 1 |
| Suzuki, M | 2 |
| Eissa, MM | 5 |
| El-Azzouni, MZ | 4 |
| El-Khordagui, LK | 3 |
| Abdel Bary, A | 2 |
| El-Moslemany, RM | 3 |
| Abdel Salam, SA | 2 |
| de Vries, MR | 2 |
| Ewing, MM | 1 |
| de Jong, RCM | 2 |
| MacArthur, MR | 1 |
| Karper, JC | 1 |
| Peters, EAB | 1 |
| Nordzell, M | 1 |
| Karabina, SAP | 1 |
| Sexton, D | 1 |
| Dahlbom, I | 1 |
| Bergman, A | 1 |
| Mitchell, JR | 1 |
| Frostegård, J | 1 |
| Kuiper, J | 1 |
| Ninio, E | 1 |
| Jukema, JW | 2 |
| Pettersson, K | 2 |
| Quax, PHA | 2 |
| Pluijmert, NJ | 1 |
| Atsma, DE | 1 |
| Le Grand, M | 1 |
| Berges, R | 1 |
| Pasquier, E | 1 |
| Montero, MP | 1 |
| Borge, L | 1 |
| Carrier, A | 1 |
| Vasseur, S | 1 |
| Bourgarel, V | 1 |
| Buric, D | 1 |
| André, N | 1 |
| Braguer, D | 1 |
| Carré, M | 1 |
| Liu, G | 1 |
| Tsai, HI | 1 |
| Zeng, X | 1 |
| Zuo, Y | 1 |
| Tao, W | 1 |
| Han, J | 1 |
| Mei, L | 1 |
| Wijnant, GJ | 1 |
| Van Bocxlaer, K | 2 |
| Yardley, V | 2 |
| Murdan, S | 2 |
| Croft, SL | 2 |
| Koch, G | 1 |
| Wermser, C | 1 |
| Acosta, IC | 1 |
| Kricks, L | 1 |
| Stengel, ST | 1 |
| Yepes, A | 1 |
| Lopez, D | 1 |
| Gao, R | 1 |
| Wang, L | 2 |
| Bai, T | 1 |
| Zhang, Y | 1 |
| Bo, H | 1 |
| Shu, Y | 1 |
| Zhu, F | 1 |
| Kai, J | 1 |
| Chen, L | 1 |
| Wu, M | 1 |
| Dong, J | 1 |
| Wang, Q | 1 |
| Zeng, LH | 1 |
| Miyashita, K | 1 |
| Ohori, J | 1 |
| Nagano, H | 1 |
| Fukuyama, S | 1 |
| Kurono, Y | 1 |
| Valdivieso, E | 1 |
| Mejías, F | 1 |
| Carrillo, E | 1 |
| Sánchez, C | 1 |
| Moreno, J | 1 |
| Blank, M | 4 |
| Bashi, T | 3 |
| Lachnish, J | 2 |
| Ben-Ami-Shor, D | 1 |
| Shovman, O | 1 |
| Fridkin, M | 3 |
| Eisenstein, M | 1 |
| Volkov, A | 2 |
| Barshack, I | 1 |
| Shoenfeld, Y | 4 |
| Ahmed, R | 1 |
| Cadman, ET | 1 |
| Snapper, CM | 1 |
| Lawrence, RA | 1 |
| Kambe, Y | 1 |
| Mahara, A | 1 |
| Tanaka, H | 1 |
| Kakinoki, S | 1 |
| Fukazawa, K | 1 |
| Liu, Y | 2 |
| Kyomoto, M | 3 |
| Minatoya, K | 1 |
| Ishihara, K | 5 |
| Yamaoka, T | 1 |
| Álvarez-Velilla, R | 1 |
| Gutiérrez-Corbo, MDC | 1 |
| Punzón, C | 1 |
| Pérez-Pertejo, MY | 1 |
| Balaña-Fouce, R | 1 |
| Fresno, M | 1 |
| Reguera, RM | 1 |
| Neira, LF | 1 |
| Mantilla, JC | 1 |
| Escobar, P | 1 |
| Yousf, S | 1 |
| Sardesai, DM | 1 |
| Mathew, AB | 1 |
| Khandelwal, R | 1 |
| Acharya, JD | 1 |
| Sharma, S | 1 |
| Chugh, J | 1 |
| de Castro, NM | 1 |
| Yaqoob, P | 1 |
| de la Fuente, M | 1 |
| Baeza, I | 1 |
| Claus, SP | 1 |
| van Zyl, JM | 1 |
| Smith, J | 1 |
| Hawtrey, A | 1 |
| Polat, ZA | 2 |
| Walochnik, J | 2 |
| Obwaller, A | 2 |
| Vural, A | 2 |
| Dursun, A | 1 |
| Arici, MK | 1 |
| Sharif, O | 1 |
| Matt, U | 1 |
| Saluzzo, S | 1 |
| Lakovits, K | 1 |
| Haslinger, I | 1 |
| Furtner, T | 1 |
| Doninger, B | 1 |
| Knapp, S | 1 |
| Verhaar, AP | 1 |
| Wildenberg, ME | 1 |
| te Velde, AA | 1 |
| Meijer, SL | 1 |
| Vos, AC | 1 |
| Duijvestein, M | 1 |
| Peppelenbosch, MP | 1 |
| Hommes, DW | 1 |
| van den Brink, GR | 1 |
| Zhang, J | 1 |
| Bi, M | 1 |
| Zhong, F | 1 |
| Jiao, X | 1 |
| Zhang, D | 1 |
| Dong, Q | 1 |
| Oyama, T | 1 |
| Takeuchi, H | 1 |
| Matsuda, S | 1 |
| Ozawa, S | 1 |
| Kitajima, M | 1 |
| Kitagawa, Y | 1 |
| Majewska-Szczepanik, M | 1 |
| Yamamoto, N | 1 |
| Askenase, PW | 1 |
| Szczepanik, M | 1 |
| Coelho, AC | 2 |
| Trinconi, CT | 2 |
| Costa, CH | 1 |
| Uliana, SR | 2 |
| Fortin, A | 3 |
| Caridha, DP | 1 |
| Leed, S | 1 |
| Ngundam, F | 1 |
| Sena, J | 1 |
| Bosschaerts, T | 2 |
| Parriott, S | 1 |
| Hickman, MR | 1 |
| Hudson, TH | 1 |
| Grogl, M | 1 |
| Izadpanah, K | 1 |
| Freyer, D | 1 |
| Weber, JR | 1 |
| Braun, JS | 1 |
| Santarem, AA | 1 |
| Greggianin, GF | 1 |
| Debastiani, RG | 1 |
| Ribeiro, JB | 1 |
| Polli, DA | 1 |
| Sampaio, RN | 1 |
| Jeon, MJ | 1 |
| Ahn, S | 1 |
| Lee, C | 1 |
| Kim, OH | 1 |
| Oh, BC | 1 |
| Yu, U | 1 |
| Kim, H | 1 |
| Zeng, XF | 1 |
| Ma, Y | 1 |
| Yang, L | 1 |
| Zhou, L | 1 |
| Xin, Y | 1 |
| Chang, L | 1 |
| Zhang, JR | 1 |
| Hao, X | 1 |
| Parchim, NF | 1 |
| Wang, W | 1 |
| Iriyama, T | 1 |
| Ashimi, OA | 1 |
| Siddiqui, AH | 1 |
| Blackwell, S | 1 |
| Sibai, B | 1 |
| Kellems, RE | 1 |
| Xia, Y | 1 |
| Ben-Ami Shor, D | 2 |
| Bizzaro, G | 1 |
| Barshak, I | 2 |
| Paulussen, C | 1 |
| Boulet, G | 1 |
| Cos, P | 3 |
| Gang, TB | 1 |
| Hanley, GA | 1 |
| Agrawal, A | 1 |
| Kinoshita, M | 1 |
| Kikkawa, YS | 1 |
| Sakamoto, T | 1 |
| Kondo, K | 1 |
| Konno, T | 3 |
| Pawsey, N | 1 |
| Yamasoba, T | 1 |
| Doert, A | 1 |
| Pilatus, U | 1 |
| Zanella, F | 1 |
| Müller, WE | 1 |
| Eckert, GP | 1 |
| Chen, R | 1 |
| Wang, Y | 1 |
| Ning, R | 1 |
| Hu, J | 1 |
| Liu, W | 1 |
| Xiong, J | 1 |
| Wu, L | 1 |
| Liu, J | 1 |
| Hu, G | 1 |
| Yang, J | 1 |
| Versini, M | 1 |
| Gendelman, O | 1 |
| Zhu, J | 1 |
| Wu, Y | 1 |
| Guo, Y | 1 |
| Tang, Q | 1 |
| Lu, T | 1 |
| Cai, W | 1 |
| Huang, H | 1 |
| Patel, PS | 1 |
| Kearney, JF | 1 |
| Mondelaers, A | 3 |
| Delputte, P | 2 |
| Mudd, AT | 1 |
| Getty, CM | 1 |
| Sutton, BP | 1 |
| Dilger, RN | 1 |
| Amer, EI | 2 |
| Younis, LK | 1 |
| Shen, J | 1 |
| Hong, Y | 1 |
| Zhao, Q | 1 |
| Zhang, JL | 1 |
| de Morais-Teixeira, E | 1 |
| Aguiar, MG | 2 |
| Soares de Souza Lima, B | 1 |
| Ferreira, LA | 2 |
| Rabello, A | 1 |
| Bondy, J | 1 |
| Osharovich, S | 1 |
| Storm, J | 1 |
| Durning, G | 1 |
| McAuliffe, T | 1 |
| Fan, X | 1 |
| Centa, M | 1 |
| Gruber, S | 1 |
| Nilsson, D | 1 |
| Polyzos, KA | 1 |
| Johansson, DK | 1 |
| Hansson, GK | 1 |
| Ketelhuth, DF | 1 |
| Binder, CJ | 1 |
| Malin, S | 1 |
| Cordero, MI | 1 |
| Just, N | 1 |
| Poirier, GL | 1 |
| Sandi, C | 1 |
| Vishwakarma, P | 2 |
| Parmar, N | 1 |
| Yadav, PK | 1 |
| Chandrakar, P | 1 |
| Kar, S | 1 |
| Reimão, JQ | 1 |
| Ramadan, AA | 1 |
| Beyers, J | 1 |
| Lachaud, L | 1 |
| Dorlo, TP | 1 |
| Ratna, A | 1 |
| Arora, SK | 1 |
| Wang, N | 1 |
| Guo, D | 1 |
| Tong, G | 1 |
| Zhu, X | 1 |
| Tiwari, B | 1 |
| Pahuja, R | 1 |
| Kumar, P | 1 |
| Rath, SK | 1 |
| Gupta, KC | 1 |
| Goyal, N | 1 |
| League-Pascual, JC | 1 |
| Lester-McCully, CM | 1 |
| Shandilya, S | 1 |
| Ronner, L | 1 |
| Rodgers, L | 1 |
| Cruz, R | 1 |
| Peer, CJ | 1 |
| Figg, WD | 1 |
| Warren, KE | 1 |
| Shirao, S | 1 |
| Fujisawa, H | 1 |
| Kudo, A | 1 |
| Kurokawa, T | 1 |
| Yoneda, H | 1 |
| Kunitsugu, I | 1 |
| Ogasawara, K | 1 |
| Soma, M | 1 |
| Kobayashi, S | 1 |
| Ogawa, A | 1 |
| Manna, L | 1 |
| Vitale, F | 1 |
| Reale, S | 1 |
| Picillo, E | 1 |
| Neglia, G | 1 |
| Vescio, F | 1 |
| Gravino, AE | 1 |
| Tsang, TM | 1 |
| Haselden, JN | 1 |
| Holmes, E | 1 |
| Aksu, B | 2 |
| Umit, H | 1 |
| Kanter, M | 1 |
| Guzel, A | 1 |
| Inan, M | 1 |
| Civelek, S | 1 |
| Aktas, C | 1 |
| Uzun, H | 1 |
| de Vries, NA | 1 |
| Beijnen, JH | 1 |
| van Tellingen, O | 1 |
| Serrano-Martín, X | 1 |
| Payares, G | 1 |
| De Lucca, M | 1 |
| Martinez, JC | 1 |
| Mendoza-León, A | 1 |
| Benaim, G | 1 |
| Silva, DL | 1 |
| Nunan, FA | 1 |
| Nunan, EA | 1 |
| Fernandes, AP | 1 |
| Bäumer, W | 1 |
| Wlaź, P | 1 |
| Jennings, G | 1 |
| Rundfeldt, C | 1 |
| Ishiyama, N | 2 |
| Moro, T | 2 |
| Ohe, T | 2 |
| Miura, T | 2 |
| Ohyama, T | 2 |
| Kimura, M | 2 |
| Nakamura, K | 2 |
| Kawaguchi, H | 2 |
| Becher, OJ | 1 |
| Hambardzumyan, D | 1 |
| Walker, TR | 1 |
| Helmy, K | 1 |
| Nazarian, J | 1 |
| Albrecht, S | 1 |
| Hiner, RL | 1 |
| Gall, S | 1 |
| Huse, JT | 1 |
| Jabado, N | 1 |
| MacDonald, TJ | 1 |
| Holland, EC | 1 |
| Brodeur, GM | 1 |
| Li, Z | 1 |
| Tan, F | 1 |
| Liewehr, DJ | 1 |
| Steinberg, SM | 1 |
| Thiele, CJ | 1 |
| Mendel, I | 1 |
| Shoham, A | 1 |
| Propheta-Meiran, O | 1 |
| Ishai, E | 1 |
| Halperin, G | 1 |
| Feige, E | 1 |
| Breitbart, E | 1 |
| Sane, SA | 2 |
| Shakya, N | 2 |
| Gupta, S | 2 |
| Baddour, NM | 1 |
| Gougoulias, N | 1 |
| Maffulli, N | 1 |
| Saito, T | 1 |
| Wargo, MJ | 1 |
| Gross, MJ | 1 |
| Rajamani, S | 1 |
| Allard, JL | 1 |
| Lundblad, LK | 1 |
| Allen, GB | 1 |
| Vasil, ML | 1 |
| Leclair, LW | 1 |
| Hogan, DA | 1 |
| Bajpai, P | 1 |
| Andoh, T | 1 |
| Haza, S | 1 |
| Saito, A | 1 |
| Kuraishi, Y | 1 |
| Campos Vieira, N | 1 |
| Vacus, J | 1 |
| Fournet, A | 1 |
| Baudouin, R | 1 |
| Bories, C | 2 |
| Séon-Méniel, B | 1 |
| Figadère, B | 1 |
| Loiseau, PM | 2 |
| Gupta, R | 1 |
| Kushawaha, PK | 1 |
| Samant, M | 1 |
| Jaiswal, AK | 1 |
| Baharia, RK | 1 |
| Dube, A | 2 |
| Debache, K | 1 |
| Hemphill, A | 1 |
| Wege, AK | 1 |
| Florian, C | 1 |
| Ernst, W | 1 |
| Zimara, N | 1 |
| Schleicher, U | 1 |
| Hanses, F | 1 |
| Schmid, M | 1 |
| Ritter, U | 1 |
| Srivastava, A | 1 |
| Sweat, JM | 1 |
| Azizan, A | 1 |
| Vesely, B | 1 |
| Kyle, DE | 1 |
| Liu, X | 1 |
| Verbeken, E | 1 |
| Li, S | 1 |
| De Scheerder, I | 1 |
| Griffin, JL | 1 |
| Cemal, CK | 1 |
| Pook, MA | 1 |
| Iwasaki, Y | 1 |
| Nakabayashi, N | 1 |
| Kipshidze, NN | 1 |
| Iversen, P | 1 |
| Kim, HS | 1 |
| Yiazdi, H | 1 |
| Dangas, G | 1 |
| Seaborn, R | 1 |
| New, G | 1 |
| Tio, F | 1 |
| Waksman, R | 1 |
| Mehran, R | 1 |
| Tsapenko, M | 1 |
| Stone, GW | 1 |
| Roubin, GS | 1 |
| Iyer, S | 1 |
| Leon, MB | 1 |
| Moses, JW | 1 |
| Yagmurlu, A | 1 |
| Bingol-Kologlu, M | 1 |
| Renda, N | 1 |
| Altinok, G | 1 |
| Fitoz, S | 1 |
| Gokcora, IH | 1 |
| Dindar, H | 1 |
| Singh, N | 2 |
| Sundar, S | 1 |
| Collingwood, R | 1 |
| Gibson, L | 1 |
| Sedlik, S | 1 |
| Virmani, R | 1 |
| Carter, AJ | 1 |
| Papagiannaros, A | 1 |
| Demetzos, C | 1 |
| Faria-Neto, JR | 1 |
| Chyu, KY | 1 |
| Li, X | 1 |
| Dimayuga, PC | 1 |
| Yano, J | 1 |
| Cercek, B | 1 |
| Shah, PK | 1 |
| Widmer, F | 1 |
| Wright, LC | 1 |
| Obando, D | 1 |
| Handke, R | 1 |
| Ganendren, R | 1 |
| Ellis, DH | 1 |
| Sorrell, TC | 1 |
| Sindermann, H | 1 |
| Engel, J | 1 |
| Chao, TK | 1 |
| Rifai, A | 1 |
| Ka, SM | 1 |
| Yang, SM | 1 |
| Shui, HA | 1 |
| Lin, YF | 1 |
| Sytwu, HK | 1 |
| Lee, WH | 1 |
| Kung, JT | 1 |
| Chen, A | 1 |
| Berrocal, DH | 1 |
| González, GE | 1 |
| Morales, C | 1 |
| Gelpi, RJ | 1 |
| Grinfeld, LR | 1 |
| Vasseneix, C | 1 |
| Gargala, G | 1 |
| François, A | 1 |
| Hellot, MF | 1 |
| Duclos, C | 1 |
| Muraine, M | 1 |
| Benichou, J | 1 |
| Ballet, JJ | 1 |
| Brasseur, G | 1 |
| Favennec, L | 1 |
| Fris, M | 1 |
| Tessem, MB | 1 |
| Saether, O | 1 |
| Midelfart, A | 1 |
| Hong, W | 1 |
| Mason, K | 1 |
| Jurcisek, J | 1 |
| Novotny, L | 1 |
| Bakaletz, LO | 1 |
| Swords, WE | 1 |
| Eibl, KH | 1 |
| Lewis, GP | 1 |
| Betts, K | 1 |
| Linberg, KA | 1 |
| Gandorfer, A | 1 |
| Kampik, A | 1 |
| Fisher, SK | 1 |
| Iqbal, J | 1 |
| Bukhari, I | 1 |
| Jamshid, M | 1 |
| Bashir, S | 1 |
| Masoom Yasinzai, M | 1 |
| Anwar, M | 1 |
| Dubé, H | 1 |
| Clifford, AG | 1 |
| Barry, CM | 1 |
| Schwarten, DE | 1 |
| Schwartz, LB | 1 |
| Han, Y | 1 |
| Liang, M | 1 |
| Kang, J | 1 |
| Qi, Y | 1 |
| Deng, J | 1 |
| Xu, K | 1 |
| Yan, C | 1 |
| Padilla, ND | 1 |
| van Vliet, AK | 1 |
| Schoots, IG | 1 |
| Valls Seron, M | 1 |
| Maas, MA | 1 |
| Peltenburg, EE | 1 |
| de Vries, A | 1 |
| Niessen, HW | 1 |
| Hack, CE | 1 |
| van Gulik, TM | 1 |
| Barbier, M | 1 |
| Oliver, A | 1 |
| Rao, J | 1 |
| Hanna, SL | 1 |
| Goldberg, JB | 1 |
| Albertí, S | 1 |
| Cansev, M | 1 |
| Ilcol, YO | 1 |
| Yilmaz, MS | 1 |
| Hamurtekin, E | 1 |
| Ulus, IH | 1 |
| Chung, YL | 1 |
| Troy, H | 1 |
| Kristeleit, R | 1 |
| Aherne, W | 1 |
| Jackson, LE | 1 |
| Atadja, P | 1 |
| Griffiths, JR | 1 |
| Judson, IR | 1 |
| Workman, P | 1 |
| Leach, MO | 1 |
| Beloueche-Babari, M | 1 |
| Teichert, F | 1 |
| Verschoyle, RD | 1 |
| Greaves, P | 1 |
| Edwards, RE | 1 |
| Teahan, O | 1 |
| Jones, DJ | 1 |
| Wilson, ID | 1 |
| Farmer, PB | 1 |
| Steward, WP | 1 |
| Gant, TW | 1 |
| Gescher, AJ | 1 |
| Keun, HC | 1 |
| Scher, I | 1 |
| Häfner, D | 1 |
| Beume, R | 1 |
| Kilian, U | 1 |
| Krasznai, G | 1 |
| Lachmann, B | 1 |
| Wiswell, TE | 1 |
| Peabody, SS | 1 |
| Davis, JM | 1 |
| Slayter, MV | 1 |
| Bent, RC | 1 |
| Merritt, TA | 1 |
| Bruni, R | 1 |
| Fan, BR | 1 |
| David-Cu, R | 1 |
| Taeusch, HW | 1 |
| Walther, FJ | 1 |
| Sood, SL | 2 |
| Balaraman, V | 2 |
| Finn, KC | 1 |
| Wilkerson, SY | 1 |
| Mundie, TG | 1 |
| Easa, D | 2 |
| Jones, HC | 1 |
| Harris, NG | 1 |
| Rocca, JR | 1 |
| Andersohn, RW | 1 |
| Al-Qaoud, KM | 1 |
| Fleischer, B | 1 |
| Hoerauf, A | 1 |
| Fok, TF | 1 |
| al-Essa, M | 1 |
| Dolovich, M | 1 |
| Rasid, F | 1 |
| Kirpalani, H | 1 |
| Meister, J | 1 |
| Ku, TL | 1 |
| Tam, E | 1 |
| Killeen, J | 1 |
| Uyehara, CF | 1 |
| Egan, E | 1 |
| Jernigan, HM | 1 |
| Zigler, JS | 1 |
| Blum, PS | 1 |
| Merola, LO | 1 |
| Stimbert, CD | 1 |
| Kuiper, KK | 1 |
| Robinson, KA | 1 |
| Chronos, NA | 1 |
| Cui, J | 1 |
| Palmer, SJ | 1 |
| Nordrehaug, JE | 1 |
| Arndt, D | 1 |
| Zeisig, R | 1 |
| Fichtner, I | 1 |
| Teppke, AD | 1 |
| Fahr, A | 1 |
| Vejchapipat, P | 1 |
| Williams, SR | 1 |
| Spitz, L | 1 |
| Pierro, A | 1 |
| Tong, HH | 1 |
| Blue, LE | 1 |
| James, MA | 1 |
| Chen, YP | 1 |
| DeMaria, TF | 1 |
| Murray, HW | 1 |
| Farber, SA | 1 |
| Slack, BE | 1 |
| Blusztajn, JK | 1 |
| Eue, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma[NCT01106794] | 100 participants (Anticipated) | Observational | 2010-04-30 | Recruiting | |||
| Range of Motion and Function Following Primary Repair of Traumatic Zone 1 or Zone 2 Digit Flexor Tendon Injuries - Impact of Tranexamic Acid Use - A Prospective Study[NCT04178655] | Early Phase 1 | 48 participants (Anticipated) | Interventional | 2019-11-30 | Not yet recruiting | ||
| Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia.[NCT01462500] | Phase 4 | 60 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for phosphorylcholine and Disease Models, Animal
| Article | Year |
|---|---|
Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Prolif | 2020 |
Helminth-Related Tuftsin-Phosphorylcholine Compound and its Interplay with Autoimmune Diseases.
Topics: Animals; Autoimmune Diseases; Disease Models, Animal; Helminthiasis; Helminths; Humans; Immunologic | 2019 |
High-grade glioma mouse models and their applicability for preclinical testing.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biomark | 2009 |
Development of miltefosine as an oral treatment for leishmaniasis.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Antineoplastic Agents; Antiprotozoal Age | 2006 |
The CBA/N mouse strain: an experimental model illustrating the influence of the X-chromosome on immunity.
Topics: Animals; Antibody Affinity; Antigens, T-Independent; B-Lymphocytes; Disease Models, Animal; Female; | 1982 |
140 other studies available for phosphorylcholine and Disease Models, Animal
| Article | Year |
|---|---|
Lipid raft-disrupting miltefosine preferentially induces the death of colorectal cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Me | 2021 |
Preclinical In Vivo Safety of Poly-Phosphorylated Superlubrication Vectors for the Treatment of Osteoarthritis.
Topics: Animals; Cartilage, Articular; Disease Models, Animal; Humans; Injections, Intra-Articular; Liposome | 2022 |
Sphingosylphosphorylcholine ameliorates experimental sjögren's syndrome by regulating salivary gland inflammation and hypofunction, and regulatory B cells.
Topics: Animals; B-Lymphocytes, Regulatory; Disease Models, Animal; Female; Humans; Inflammation; Mice; Mice | 2022 |
Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine.
Topics: Administration, Oral; Animals; Antimony; Antiprotozoal Agents; Disease Models, Animal; Female; Leish | 2019 |
Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.
Topics: Administration, Cutaneous; Amphotericin B; Animals; Antiprotozoal Agents; Disease Models, Animal; Dr | 2020 |
Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits.
Topics: Animals; Antifungal Agents; Dermatomycoses; Disease Models, Animal; Disease Progression; Dose-Respon | 2020 |
Efficient reduction of fibrous capsule formation around silicone breast implants densely grafted with 2-methacryloyloxyethyl phosphorylcholine (MPC) polymers by heat-induced polymerization.
Topics: Animals; Breast Implants; Dimethylpolysiloxanes; Disease Models, Animal; Female; Foreign-Body Reacti | 2020 |
Exogenous Vitamin C-Triggered Surface Charge Conversion of pH/Reduction-Responsive Micelles for the Enhanced Tumor-Specific Activity of Loaded Doxorubicin.
Topics: Allografts; Animals; Antineoplastic Agents; Ascorbic Acid; Cell Survival; Disease Models, Animal; Do | 2020 |
Biological risk assessment of miltefosine in concomitant infection with opportunistic toxoplasmosis.
Topics: Animal Structures; Animals; Disease Models, Animal; Female; Immunologic Factors; Injections, Intrape | 2019 |
Glutamine supplementation improves the efficacy of miltefosine treatment for visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Dietary Supplements; Disease Models, Animal; Female; Glutamine; Human | 2020 |
Complexes between C-Reactive Protein and Very Low Density Lipoprotein Delay Bacterial Clearance in Sepsis.
Topics: Aged; Animals; Bacteremia; C-Reactive Protein; Disease Models, Animal; Female; Humans; Kupffer Cells | 2020 |
Comparative evaluation of nucleic acid stabilizing reagents for RNA- and DNA-based Leishmania detection in blood as proxy for visceral burdens.
Topics: Animals; Cricetinae; Disease Models, Animal; DNA; DNA, Kinetoplast; Female; Humans; Indicators and R | 2020 |
Combination treatment of perifosine and valsartan showed more efficiency in protecting against pressure overload induced mouse heart failure.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Glycogen Synthase Kinase 3 beta; Heart F | 2020 |
Phase variation with altering phosphorylcholine expression of nontypeable Haemophilus influenzae affects bacteria clearance and mucosal immune response in the middle ear and nasopharynx.
Topics: Animals; C-Reactive Protein; Cytokines; Disease Models, Animal; Ear, Middle; Haemophilus Infections; | 2021 |
Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Combinations; Drug Compounding; Female; | 2020 |
Evaluation of prophylactic efficacy and safety of praziquantel-miltefosine nanocombination in experimental Schistosomiasis mansoni.
Topics: Animals; Anthelmintics; Disease Models, Animal; Drug Carriers; Drug Combinations; Granuloma; Lipids; | 2020 |
Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Atherosclerosis; Cardiovascular Diseases; | 2021 |
Phosphorylcholine antibodies restrict infarct size and left ventricular remodelling by attenuating the unreperfused post-ischaemic inflammatory response.
Topics: Animals; Antibodies, Monoclonal; Apolipoprotein E3; Disease Models, Animal; Female; Inflammation; Is | 2021 |
Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; | 2017 |
Phosphorylcholine-based stealthy nanocapsules enabling tumor microenvironment-responsive doxorubicin release for tumor suppression.
Topics: Animals; Antibiotics, Antineoplastic; Cell Survival; Disease Models, Animal; Doxorubicin; Drug Carri | 2017 |
Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Chloroquine; Disease Models, Animal; Drug Combination | 2017 |
Attenuating Staphylococcus aureus Virulence by Targeting Flotillin Protein Scaffold Activity.
Topics: Animals; Bacterial Proteins; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Endoribon | 2017 |
C-Reactive Protein Mediating Immunopathological Lesions: A Potential Treatment Option for Severe Influenza A Diseases.
Topics: Adolescent; Adult; Animals; C-Reactive Protein; Cell Line; Child; Child, Preschool; Complement Activ | 2017 |
Akt Inhibitor Perifosine Prevents Epileptogenesis in a Rat Model of Temporal Lobe Epilepsy.
Topics: Animals; Anticonvulsants; Brain; Convulsants; Disease Models, Animal; Epilepsy, Temporal Lobe; Kaini | 2018 |
Intranasal immunization with phosphorylcholine suppresses allergic rhinitis in mice.
Topics: Adjuvants, Immunologic; Administration, Intranasal; Animals; Cytokines; Dendritic Cells; Disease Mod | 2018 |
Potentiation of the leishmanicidal activity of nelfinavir in combination with miltefosine or amphotericin B.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Survival; Disease Models, Animal; Drug Synergism | 2018 |
Helminths-based bi-functional molecule, tuftsin-phosphorylcholine (TPC), ameliorates an established murine arthritis.
Topics: Animals; Arthritis, Experimental; B-Lymphocytes; Disease Models, Animal; HEK293 Cells; Helminths; Hu | 2018 |
Decreased nematode clearance and anti-phosphorylcholine-specific IgM responses in mannose-binding lectin-deficient mice.
Topics: Animals; Antibodies, Protozoan; Antibody Specificity; B-Lymphocytes; Bacterial Vaccines; Complement | 2019 |
Short-term evaluation of thromboresistance of a poly(ether ether ketone) (PEEK) mechanical heart valve with poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC)-grafted surface in a porcine aortic valve replacement model.
Topics: Animals; Aortic Valve; Benzophenones; Biocompatible Materials; Disease Models, Animal; Heart Valve P | 2019 |
A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Discovery; Female; Leishmania infantum; | 2019 |
Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis.
Topics: Administration, Topical; Animals; Antiprotozoal Agents; Biopsy; Disease Models, Animal; Drug Stabili | 2019 |
Metabolic signatures suggest o-phosphocholine to UDP-N-acetylglucosamine ratio as a potential biomarker for high-glucose and/or palmitate exposure in pancreatic β-cells.
Topics: Animals; Apoptosis; Biomarkers; Diabetes Mellitus; Disease Models, Animal; Fatty Acids, Nonesterifie | 2019 |
Premature impairment of methylation pathway and cardiac metabolic dysfunction in fa/fa obese Zucker rats.
Topics: Adipose Tissue, White; Age Factors; Animals; Betaine; Disease Models, Animal; Inositol; Liver; Magne | 2013 |
The effect of a peptide-containing synthetic lung surfactant on gas exchange and lung mechanics in a rabbit model of surfactant depletion.
Topics: Acute Lung Injury; Animals; Bronchoalveolar Lavage Fluid; Calcium; Disease Models, Animal; Drug Comb | 2013 |
Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Animals; Antiprotozoal Agents; Biguanides; Cell Line; Cell Pro | 2014 |
The scavenger receptor CD36 downmodulates the early inflammatory response while enhancing bacterial phagocytosis during pneumococcal pneumonia.
Topics: Animals; CD36 Antigens; Disease Models, Animal; Female; Immunity, Innate; Inflammation; Macrophages, | 2013 |
Miltefosine suppresses inflammation in a mouse model of inflammatory bowel disease.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cytokines; Disease Models, Animal; Humans; Immun | 2013 |
Role of CIP4 in high glucose induced epithelial--mesenchymal transition of rat peritoneal mesothelial cells.
Topics: Actins; Animals; Cadherins; Cells, Cultured; Dialysis Solutions; Disease Models, Animal; Epithelial- | 2013 |
Translymphatic chemotherapy targeting sentinel lymph nodes using a novel phospholipid polymer-Paclitaxel conjugate.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Cell Line, Tumor; Cell Survival; Disease Mo | 2014 |
Epicutaneous immunization with phosphorylcholine conjugated to bovine serum albumin (PC-BSA) and TLR9 ligand CpG alleviates pneumococcal pneumonia in mice.
Topics: Administration, Cutaneous; Animals; CpG Islands; Disease Models, Animal; Interferon-gamma; Interleuk | 2014 |
In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Resistance; Female; Humans; Leishmania; | 2014 |
Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Leishmania major; Leish | 2014 |
Brain parenchymal TNF-α and IL-1β induction in experimental pneumococcal meningitis.
Topics: Animals; Antibodies; Brain; CD18 Antigens; Colony Count, Microbial; Dipeptides; Disease Models, Anim | 2014 |
Effectiveness of miltefosine-pentoxifylline compared to miltefosine in the treatment of cutaneous leishmaniasis in C57Bl/6 mice.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Evaluation, Precli | 2014 |
High resolution in vivo 31P-MRS of the liver: potential advantages in the assessment of non-alcoholic fatty liver disease.
Topics: Animals; Disease Models, Animal; Ethanolamines; Glycerylphosphorylcholine; Liver Cirrhosis; Magnetic | 2015 |
A C-terminal truncated mutation of licC attenuates the virulence of Streptococcus pneumoniae.
Topics: Animals; Bacterial Adhesion; Cell Line; Choline-Phosphate Cytidylyltransferase; Disease Models, Anim | 2014 |
Neurokinin 3 receptor and phosphocholine transferase: missing factors for pathogenesis of C-reactive protein in preeclampsia.
Topics: Animals; Biomarkers; C-Reactive Protein; Choline-Phosphate Cytidylyltransferase; Disease Models, Ani | 2015 |
Phosphorylcholine-tuftsin compound prevents development of dextransulfate-sodium-salt induced murine colitis: implications for the treatment of human inflammatory bowel disease.
Topics: Animals; Colitis; Cytokines; Dextran Sulfate; Disease Models, Animal; Humans; Immunologic Factors; I | 2015 |
Efficacy of oleylphosphocholine (OlPC) in vitro and in a mouse model of invasive aspergillosis.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus; Aspergillus fumigatus; Azoles; Disease Model | 2015 |
C-reactive protein protects mice against pneumococcal infection via both phosphocholine-dependent and phosphocholine-independent mechanisms.
Topics: Animals; Bacterial Load; C-Reactive Protein; Disease Models, Animal; Male; Mice, Inbred C57BL; Mutan | 2015 |
Safety, reliability, and operability of cochlear implant electrode arrays coated with biocompatible polymer.
Topics: Animals; Coated Materials, Biocompatible; Cochlea; Cochlear Implantation; Cochlear Implants; Disease | 2015 |
¹H- and ¹³C-NMR spectroscopy of Thy-1-APPSL mice brain extracts indicates metabolic changes in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Br | 2015 |
Decreased carboxylesterases expression and hydrolytic activity in type 2 diabetic mice through Akt/mTOR/HIF-1α/Stra13 pathway.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Blood Glucose; Carboxylic Ester Hydrolases; D | 2015 |
Successful modulation of murine lupus nephritis with tuftsin-phosphorylcholine.
Topics: Animals; Autoantibodies; Cytokines; Disease Models, Animal; Forkhead Transcription Factors; Glomerul | 2015 |
Choline Alleviates Parenteral Nutrition-Associated Duodenal Motility Disorder in Infant Rats.
Topics: Animals; Animals, Newborn; Betaine; Choline; Disease Models, Animal; Duodenum; Gastrointestinal Moti | 2016 |
Neonatal exposure to pneumococcal phosphorylcholine modulates the development of house dust mite allergy during adult life.
Topics: Age Factors; Animals; Animals, Newborn; Antibodies; Antigen Presentation; Antigen-Presenting Cells; | 2015 |
In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Drug Resistance; Female; Leishman | 2015 |
Perinatal choline deficiency delays brain development and alters metabolite concentrations in the young pig.
Topics: Animals; Animals, Newborn; Brain; Choline; Choline Deficiency; Diet; Diffusion Tensor Imaging; Disea | 2016 |
Could miltefosine be used as a therapy for toxoplasmosis?
Topics: Animals; Antiprotozoal Agents; Brain; Disease Models, Animal; Infectious Encephalitis; Liver; Mice; | 2015 |
Preclinical evaluation of perifosine as a potential promising anti-rhabdomyosarcoma agent.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Disease Models, Animal; | 2016 |
Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
Topics: Administration, Oral; Administration, Topical; Animals; Antiprotozoal Agents; Appointments and Sched | 2015 |
Haemophilus influenzae LicB contributes to lung damage in an aged mice co-infection model.
Topics: Age Factors; Amino Acid Sequence; Animals; Bacterial Proteins; Choline; Coinfection; Disease Models, | 2016 |
Atherosclerosis Susceptibility in Mice Is Independent of the V1 Immunoglobulin Heavy Chain Gene.
Topics: Animals; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; B-Lymphocytes; Disease Models, | 2016 |
Effects of paternal and peripubertal stress on aggression, anxiety, and metabolic alterations in the lateral septum.
Topics: Age Factors; Aggression; Animals; Animals, Newborn; Anxiety Disorders; Aspartic Acid; Creatine; Dise | 2016 |
15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Apoptosis; Cell Line; Cricetulus; Disease Models, Ani | 2016 |
Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Interactions; Drug | 2016 |
Miltefosine lipid nanocapsules: Intersection of drug repurposing and nanotechnology for single dose oral treatment of pre-patent schistosomiasis mansoni.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Repositioning; Granuloma; Liver; Mice; N | 2016 |
Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Resistance; Female; Humans; Leishmania i | 2016 |
Pharmacokinetics and pharmacodynamics of oleylphosphocholine in a hamster model of visceral leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Area Under Curve; Chemoprevention; Disease Mode | 2016 |
Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.
Topics: Administration, Topical; Animals; Cells, Cultured; Disease Models, Animal; Drug Compounding; Female; | 2016 |
Molecular detection of infection homogeneity and impact of miltefosine treatment in a Syrian golden hamster model of Leishmania donovani and L. infantum visceral leishmaniasis.
Topics: Animals; Cricetinae; Disease Models, Animal; Female; Leishmania donovani; Leishmania infantum; Leish | 2016 |
Leishmania recombinant antigen modulates macrophage effector function facilitating early clearance of intracellular parasites.
Topics: Animals; Antigens, Protozoan; Cricetinae; Disease Models, Animal; Leishmania; Leishmaniasis; Macroph | 2016 |
Iron Chelation Nanoparticles with Delayed Saturation as an Effective Therapy for Parkinson Disease.
Topics: Animals; Behavior, Animal; Blood-Brain Barrier; Brain; Cell Survival; Disease Models, Animal; Humans | 2017 |
Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Cell Proliferation; Cricetinae; Curcumin; Disea | 2017 |
Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model.
Topics: Administration, Intranasal; Animals; Antineoplastic Agents; Blood-Brain Barrier; Dacarbazine; Diseas | 2017 |
Inhibitory effects of eicosapentaenoic acid on chronic cerebral vasospasm after subarachnoid hemorrhage: possible involvement of a sphingosylphosphorylcholine-rho-kinase pathway.
Topics: Animals; Basilar Artery; Benzopyrans; Cerebral Angiography; Cisterna Magna; Disease Models, Animal; | 2008 |
Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Disease Models, Animal; Disease Reservoirs; Dog Diseases | 2009 |
Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington's disease.
Topics: Animals; Behavior, Animal; Brain; Brain Stem; Cerebellum; Cerebral Cortex; Choline; Corpus Striatum; | 2009 |
Effects of sphingosylphosphorylcholine against cholestatic oxidative stress and liver damage in the common bile duct ligated rats.
Topics: Analysis of Variance; Animals; Cholestasis, Extrahepatic; Common Bile Duct; Disease Models, Animal; | 2009 |
Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis.
Topics: Amiodarone; Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Drug Synergism; Femal | 2009 |
Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
Topics: Administration, Oral; Administration, Topical; Animals; Disease Models, Animal; Drug Therapy, Combin | 2009 |
The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models.
Topics: Administration, Oral; Administration, Topical; Animals; Anti-Inflammatory Agents; Arachidonic Acid; | 2010 |
The prevention of peritendinous adhesions by a phospholipid polymer hydrogel formed in situ by spontaneous intermolecular interactions.
Topics: Achilles Tendon; Animals; Biomechanical Phenomena; Chickens; Disease Models, Animal; Elasticity; Hyd | 2010 |
Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma.
Topics: Animals; Brain Stem Neoplasms; Combined Modality Therapy; Disease Models, Animal; Genetic Engineerin | 2010 |
Getting into the AKT.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Surv | 2010 |
In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tu | 2010 |
A Lecinoxoid, an oxidized phospholipid small molecule, constrains CNS autoimmune disease.
Topics: Animals; Bone Marrow Cells; Bromodeoxyuridine; CD4 Antigens; Cell Differentiation; Central Nervous S | 2010 |
Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Cell Proliferation; Cinnamates; Cricetinae; Disease Models, Animal; D | 2011 |
Miltefosine, a promising novel agent for schistosomiasis mansoni.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Liver; Male; Mice; Microscopy, Electron, Scan | 2011 |
Peritendinous adhesions that form after the repair of lacerated digital flexor tendons cause stiffness and functional impairment.
Topics: Achilles Tendon; Animals; Biocompatible Materials; Disease Models, Animal; Hydrogel, Polyethylene Gl | 2011 |
Reduction of Peritendinous adhesions by hydrogel containing biocompatible phospholipid polymer MPC for tendon repair.
Topics: Achilles Tendon; Animals; Biocompatible Materials; Disease Models, Animal; Hydrogel, Polyethylene Gl | 2011 |
Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection.
Topics: Animals; Antifungal Agents; Bronchoalveolar Lavage Fluid; Cystic Fibrosis; Disease Models, Animal; H | 2011 |
Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
Topics: Animals; Antiprotozoal Agents; Cinnamates; Cricetinae; Disease Models, Animal; Drug Therapy, Combina | 2011 |
Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Administration, Topical; Animals; Antiprotozoal Agents; Benzam | 2012 |
Involvement of leukotriene B4 in spontaneous itch-related behaviour in NC mice with atopic dermatitis-like skin lesions.
Topics: Administration, Topical; Animals; Arachidonate 5-Lipoxygenase; Dermatitis, Atopic; Disease Models, A | 2011 |
Antileishmanial activity of a formulation of 2-n-propylquinoline by oral route in mice model.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Disease Models, Anim | 2011 |
Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Cell Proliferation; Cricetinae; Cytokines; Dis | 2012 |
Effects of miltefosine treatment in fibroblast cell cultures and in mice experimentally infected with Neospora caninum tachyzoites.
Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Chlorocebus aethiops; Coccidiosis; Disease Models, A | 2012 |
Leishmania major infection in humanized mice induces systemic infection and provokes a nonprotective human immune response.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Humans; Immune Evasion; Leishmania major; Lei | 2012 |
Real-time PCR to quantify Leishmania donovani in hamsters.
Topics: Amidines; Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; DNA, Kinetoplast; Dose- | 2013 |
Local methylprednisolone delivery using a BiodivYsio phosphorylcholine-coated drug-delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model.
Topics: Animals; Anti-Inflammatory Agents; Blood Vessel Prosthesis Implantation; Coated Materials, Biocompat | 2003 |
Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3.
Topics: Animals; Ataxin-3; Brain; Cerebellum; Choline; Disease Models, Animal; gamma-Aminobutyric Acid; Gluc | 2004 |
In vitro and ex vivo blood compatibility study of 2-methacryloyloxyethyl phosphorylcholine (MPC) copolymer-coated hemodialysis hollow fibers.
Topics: Animals; Cattle; Cells, Cultured; Coated Materials, Biocompatible; Disease Models, Animal; In Vitro | 2003 |
Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model.
Topics: Animals; Blood Vessel Prosthesis Implantation; Coated Materials, Biocompatible; Coronary Angiography | 2004 |
A novel approach for preventing esophageal stricture formation: sphingosylphosphorylcholine-enhanced tissue remodeling.
Topics: Animals; Burns, Chemical; Caustics; Collagen; Contrast Media; Disease Models, Animal; Esophageal Ste | 2004 |
Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Cell Line; Cricetinae; Dis | 2005 |
Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model.
Topics: Angioplasty, Balloon, Coronary; Animals; Coated Materials, Biocompatible; Coronary Vessels; Disease | 2005 |
Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations.
Topics: Amines; Animals; Chemistry, Pharmaceutical; Disease Models, Animal; Dose-Response Relationship, Drug | 2005 |
Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice.
Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Apolipoproteins E; Atherosclerosis; Car | 2006 |
Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis.
Topics: Acyltransferases; Animals; Antifungal Agents; Cryptococcosis; Disease Models, Animal; Enzyme Inhibit | 2006 |
The endogenous immune response modulates the course of IgA-immune complex mediated nephropathy.
Topics: Animals; B-Lymphocytes; Chemokine CCL2; Disease Models, Animal; Flow Cytometry; Glomerulonephritis, | 2006 |
Irinotecan-eluting stents inhibited neointimal proliferation in hypercholesterolemic rabbit aortas.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Camptothecin; Cell Proliferation; Dietary Fats; Disease | 2006 |
A keratitis rat model for evaluation of anti-Acanthamoeba polyphaga agents.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Administration, Topical; Animals; Antiprotozoal Agents; Benzam | 2006 |
Biochemical changes in selenite cataract model measured by high-resolution MAS H NMR spectroscopy.
Topics: Amino Acids; Animals; Animals, Newborn; Cataract; Crystallins; Disease Models, Animal; Glutathione; | 2006 |
Phosphorylcholine decreases early inflammation and promotes the establishment of stable biofilm communities of nontypeable Haemophilus influenzae strain 86-028NP in a chinchilla model of otitis media.
Topics: Animals; Bacterial Proteins; Biofilms; Chinchilla; Colony Count, Microbial; Diacylglycerol Cholineph | 2007 |
The effect of alkylphosphocholines on intraretinal proliferation initiated by experimental retinal detachment.
Topics: Animals; Bromodeoxyuridine; Cell Proliferation; Disease Models, Animal; Drug Carriers; Immunohistoch | 2007 |
Hexadecyl-phosphorylcholine ointment for treatment of cutaneous leishmaniasis: an animal trial.
Topics: Administration, Cutaneous; Analysis of Variance; Animals; Anti-Infective Agents, Local; Antiprotozoa | 2006 |
Comparison of the vascular responses to balloon-expandable stenting in the coronary and peripheral circulations: long-term results in an animal model using the TriMaxx stent.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Animals; Arterial Occlusive Diseases; Coated M | 2007 |
Estrogen-eluting stent implantation inhibits neointimal formation and extracellular signal-regulated kinase activation.
Topics: Analysis of Variance; Animals; Blotting, Western; Coated Materials, Biocompatible; Coronary Restenos | 2007 |
C-reactive protein and natural IgM antibodies are activators of complement in a rat model of intestinal ischemia and reperfusion.
Topics: Animals; C-Reactive Protein; Capillary Permeability; Complement Activation; Complement C3; Complemen | 2007 |
Novel phosphorylcholine-containing protein of Pseudomonas aeruginosa chronic infection isolates interacts with airway epithelial cells.
Topics: Acute Disease; Animals; Bacterial Proteins; Chronic Disease; Disease Models, Animal; Humans; Mice; M | 2008 |
Peripheral administration of CDP-choline, phosphocholine or choline increases plasma adrenaline and noradrenaline concentrations.
Topics: Adrenal Glands; Animals; Atropine Derivatives; Autonomic Nervous System; Central Nervous System; Cho | 2008 |
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.
Topics: Acetylation; Animals; Biomarkers, Tumor; Blotting, Western; Cell Cycle; Cell Proliferation; Colonic | 2008 |
Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism.
Topics: Adenocarcinoma; Animals; Biomarkers, Tumor; Choline; Choline Kinase; Disease Models, Animal; Gene Ex | 2008 |
Dose-response comparisons of five lung surfactant factor (LSF) preparations in an animal model of adult respiratory distress syndrome (ARDS).
Topics: Animals; Biological Products; Blood Gas Analysis; Cattle; Disease Models, Animal; Dose-Response Rela | 1995 |
Surfactant therapy and high-frequency jet ventilation in the management of a piglet model of the meconium aspiration syndrome.
Topics: Animals; Animals, Newborn; Biological Products; Bronchoalveolar Lavage Fluid; Disease Models, Animal | 1994 |
Inactivation of surfactant in rat lungs.
Topics: Animals; Biological Products; Disease Models, Animal; Drug Combinations; Fatty Alcohols; Female; Hum | 1996 |
Exogenous surfactant decreases oxygenation in Escherichia coli endotoxin-treated neonatal piglets.
Topics: Animals; Animals, Newborn; Biological Products; Bronchoalveolar Lavage Fluid; Disease Models, Animal | 1996 |
Progressive changes in cortical metabolites at three stages of infantile hydrocephalus studied by in vitro NMR spectroscopy.
Topics: Age Factors; Amino Acids; Analysis of Variance; Animals; Aspartic Acid; Case-Control Studies; Cell M | 1997 |
The Xid defect imparts susceptibility to experimental murine filariosis--association with a lack of antibody and IL-10 production by B cells in response to phosphorylcholine.
Topics: Animals; Antibodies, Helminth; B-Lymphocytes; Disease Models, Animal; Disease Susceptibility; Filari | 1998 |
Nebulisation of surfactants in an animal model of neonatal respiratory distress.
Topics: Aerosols; Animals; Biological Products; Carbon Dioxide; Disease Models, Animal; Drug Combinations; F | 1998 |
Lavage administration of dilute surfactants after acute lung injury in neonatal piglets.
Topics: Animals; Animals, Newborn; Bronchoalveolar Lavage; Disease Models, Animal; Drug Combinations; Fatty | 1998 |
Effects of xylose on monkey lenses in organ culture: a model for study of sugar cataracts in a primate.
Topics: Animals; Cataract; Disease Models, Animal; Galactitol; Galactose; Glucose; Lens, Crystalline; Macaca | 1998 |
Phosphorylcholine-coated metallic stents in rabbit iliac and porcine coronary arteries.
Topics: Angiography; Animals; Arteries; Blood Vessel Prosthesis Implantation; Coated Materials, Biocompatibl | 1998 |
Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Chemistry, Pharmaceutical; Disea | 1999 |
Intestinal metabolism after ischemia-reperfusion.
Topics: Amino Acids; Analysis of Variance; Animals; Disease Models, Animal; Glucose; Intestine, Small; Ische | 2000 |
Evaluation of phase variation of nontypeable Haemophilus influenzae lipooligosaccharide during nasopharyngeal colonization and development of otitis media in the chinchilla model.
Topics: Animals; Antigens, Bacterial; Bacterial Proteins; Chinchilla; Disease Models, Animal; Genes, Bacteri | 2000 |
Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Leishmania donovani; Le | 2000 |
Acceleration of phosphatidylcholine synthesis and breakdown by inhibitors of mitochondrial function in neuronal cells: a model of the membrane defect of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Choline; Cytidine Diphosphate | 2000 |
Growth inhibition of human mammary carcinoma by liposomal hexadecylphosphocholine: Participation of activated macrophages in the antitumor mechanism.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Humans | 2001 |